WHO Approves New Malaria Treatment for Babies
The World Health Organization (WHO) has approved artesunate for use in babies. This is the first time the drug has been specifically authorized for infants. It is a key step in fighting malaria, especially in Africa.
The WHO approved artesunate for babies weighing between two and five kilograms. Malaria causes over 600,000 deaths each year, mostly in Africa. Previously, older children received this medication. The new approval reduces the risk of side effects from older treatments. Countries without testing facilities can now approve the drug's use. This helps fight malaria and lower infant mortality rates.
Summarized from the sources above. Read the originals for the full story.
Highlights
WHO Approves Drug for Babies
The World Health Organization approved the malaria drug artesunate for babies for the first time.
Treatment Targets Specific Weight
The new medication treats malaria in babies weighing two to five kilograms.
Malaria Causes Many Deaths
Malaria causes over 600,000 deaths annually, mostly in Africa.
Reduces Adverse Reactions
The new treatment aims to lower harmful reactions from older drugs.
Allows Rapid Approval
Countries can approve the drug without their own testing.
Perspectives
- The WHO approved artesunate for babies.
- The drug is for treating malaria in infants.
- This approval is a step to fight malaria.
- The drug reduces risks from previous treatments.